1Goodwin, FK, Jamison, KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression (2nd edn). Oxford University Press, 2007.
2Crump, C, Sundquist, K, Winkleby, MA, Sundquist, J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013; 70: 931–9.
3Kendall, T, Morriss, R, Mayo-Wilson, E, Marcus, E. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014; 349: g5673.
4National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. British Psychological Society, 2006.
5Correll, CU, Detraux, J, De Lepeleire, J, De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119–36.
6Cipriani, A, Hawton, K, Stockton, S, Geddes, JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
7Cohen, LS, Friedman, JM, Jefferson, JW, Johnson, EM, Weiner, ML. A reevaluation of risks of in utero exposure to lithium. J Am Med Assoc 1994; 271: 146–50.
8Kessing, LV, Gerds, TA, Feldt-Rasmussen, B, Andersen, PK, Licht, RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease a nationwide population-based study. JAMA Psychiatry 2015; 72: 1182–91.
9Fountoulakis, KN, Vieta, E, Sanchez-Moreno, J, Kaprinis, SG, Goikolea, JM, Kaprinis, GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005; 86: 1–10.
10Kessing, LV, Vradi, E, Andersen, PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016; 18: 174–82.
11Hayes, J, Prah, P, Nazareth, I, King, M, Walters, K, Petersen, I, et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS ONE 2011; 6: e28725.
12Karanti, A, Kardell, M, Lundberg, U, Landén, M. Changes in mood stabilizer prescription patterns in bipolar disorder. J Affect Disord 2016; 195: 50–6.
13Parabiaghi, A, Barbato, A, Risso, P, Fortino, I, Bortolotti, A, Merlino, L, et al. Lithium use from 2000 to 2010 in Italy: a population-based study. Pharmacopsychiatry 2015; 48: 89–94.
14Fornaro, M, De Berardis, D, Koshy, AS, Perna, G, Valchera, A, Vancampfort, D, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat 2016; 12: 719–35.
15Alvarez-Madrazo, S, McTaggart, S, Nangle, C, Nicholson, E, Bennie, M. Data resource profile: the Scottish National Prescribing Information System (PIS). Int J Epidemiol 2016; 45: 714–5f.
16Ilyas, S, Moncrieff, J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. Br J Psychiatry 2012; 200: 393–8.
17British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary . BMJ Books and Pharmaceutical Press, 2014.
18Nunes, VD, Sawyer, L, Neilson, J, Sarri, G, Cross, JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ 2012; 344: e281.
19Guthrie, B, Makubate, B, Hernandez-Santiago, V, Dreischulte, T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med 2015; 13: 1–10.
20Payne, R, Abel, G. UK indices of multiple deprivation - a way to make comparisons across constituent countries easier. Health Stat Q 2012; 53: 22–37.
21Allison, PD. Fixed Effects Regression Models. SAGE Publications, 2009.
22O'Hagan, M, Cornelius, V, Young, AH, Taylor, D. Predictors of rehospitalization in a naturalistic cohort of patients with bipolar affective disorder. Int Clin Psychopharmacol 2017; 32: 115–20.
23Viktorin, A, Lichtenstein, P, Thase, ME, Larsson, H, Lundholm, C, Magnusson, PKE, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171: 1067–73.
24Nikolova, VL, Pattanaseri, K, Hidalgo-Mazzei, D, Taylor, D, Young, AH. Is lithium monitoring NICE? Lithium monitoring in a UK secondary care setting. J Psychopharmacol 2018; 32: 408–15.
25Minchin, M, Roland, M, Richardson, J, Rowark, S, Guthrie, B. Quality of care in the United Kingdom after removal of financial incentives. N Engl J Med 2018; 379: 948–57.
26Martin, DJ, Ul-Haq, Z, Nicholl, BI, Cullen, B, Evans, J, Gill, JMR, et al. Cardiometabolic disease and features of depression and bipolar disorder: population-based, cross-sectional study. Br J Psychiatry 2016; 208: 343–51.
27Virta, LJ, Kälviäinen, R, Villikka, K, Keränen, T. Declining trend in valproate use in Finland among females of childbearing age in 2012–2016 – a nationwide registry-based outpatient study. Eur J Neurol 2018; 25: 869–94.
28Davis, KAS, Sudlow, CLM, Hotopf, M. Can mental health diagnoses in administrative data be used for research? A systematic review of the accuracy of routinely collected diagnoses. BMC Psychiatry 2016; 16: 1–11.
29James, A, Hoang, U, Seagroatt, V, Clacey, J, Goldacre, M, Leibenluft, E. A comparison of American and english hospital discharge rates for pediatric bipolar disorder, 2000 to 2010. J Am Acad Child Adolesc Psychiatry 2014; 53: 614–24.